Cargando…

Prediction of the Effects of Empagliflozin on Cardiovascular and Kidney Outcomes Based on Short-Term Changes in Multiple Risk Markers

Aims: The EMPA-REG OUTCOME trial demonstrated that the sodium-glucose cotransporter-2 inhibitor (SGLT2) empagliflozin reduces the risk of cardiovascular (CV) and kidney outcomes in patients with type 2 diabetes. We previously developed the parameter response efficacy (PRE) score, which translates dr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tye, Sok Cin, de Vries, Sieta T., Wanner, Christoph, Denig, Petra, Heerspink, Hiddo J. L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8821652/ https://www.ncbi.nlm.nih.gov/pubmed/35145402 http://dx.doi.org/10.3389/fphar.2021.786706

Ejemplares similares

Prediction of the Effects of Liraglutide on Kidney and Cardiovascular Outcomes Based on Short-Term Changes in Multiple Risk Markers
por: Tye, Sok Cin, et al.
Publicado: (2022)

Precision medicine approaches for diabetic kidney disease: opportunities and challenges
por: Tye, Sok Cin, et al.
Publicado: (2021)

Erratum to: Precision medicine approaches for diabetic kidney disease: opportunities and challenges
por: Tye, Sok Cin, et al.
Publicado: (2022)

Older Age, Polypharmacy, and Low Systolic Blood Pressure Are Associated With More Hypotension-Related Adverse Events in Patients With Type 2 Diabetes Treated With Antihypertensives
por: Ambrož, Martina, et al.
Publicado: (2021)

Less Timely Initiation of Glucose-Lowering Medication Among Younger and Male Patients With Diabetes and Similar Initiation of Blood Pressure-Lowering Medication Across Age and Sex: Trends Between 2015 and 2020
por: Ambrož, Martina, et al.
Publicado: (2022)

A novel drug response score more accurately predicts renoprotective drug effects than existing renal risk scores
por: Idzerda, Nienke M. A., et al.
Publicado: (2021)

Association of diuretic use with increased risk for long-term post-transplantation diabetes mellitus in kidney transplant recipients
por: Sokooti, Sara, et al.
Publicado: (2022)

Editorial: Sodium Glucose Co-Transporter 2 Inhibitors and Kidney Function
por: Van Raalte, Daniel H., et al.
Publicado: (2022)

Initiation of the SGLT2 inhibitor canagliflozin to prevent kidney and heart failure outcomes guided by HbA1c, albuminuria, and predicted risk of kidney failure
por: Tye, Sok Cin, et al.
Publicado: (2022)

Editorial: The role of sodium-glucose cotransporter 2 inhibitors in the management of chronic kidney disease
por: Heerspink, Hiddo J L, et al.
Publicado: (2020)

Perspectives on a Way Forward to Implementation of Precision Medicine in Patients With Diabetic Kidney Disease; Results of a Stakeholder Consensus-Building Meeting
por: Bakker, Elisabeth, et al.
Publicado: (2021)

Dapagliflozin versus empagliflozin in patients with chronic kidney disease
por: Alnsasra, Hilmi, et al.
Publicado: (2023)

Prediction of the effect of dapagliflozin on kidney and heart failure outcomes based on short-term changes in multiple risk markers
por: Idzerda, Nienke M A, et al.
Publicado: (2019)

Individual variability in response to renin angiotensin aldosterone system inhibition predicts cardiovascular outcome in patients with type 2 diabetes: A primary care cohort study
por: Apperloo, Ellen M., et al.
Publicado: (2018)

Trends in HbA(1c) thresholds for initiation of hypoglycemic agents: Impact of changed recommendations for older and frail patients
por: Ambrož, Martina, et al.
Publicado: (2020)

Short‐Term Changes in Albuminuria and Risk of Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus: A Post Hoc Analysis of the EMPA‐REG OUTCOME Trial
por: Waijer, Simke W., et al.
Publicado: (2020)

No significant association of type 2 diabetes‐related genetic risk scores with glycated haemoglobin levels after initiating metformin or sulphonylurea derivatives
por: Martono, Doti P., et al.
Publicado: (2019)

Changes in blood pressure thresholds for initiating antihypertensive medication in patients with diabetes: a repeated cross-sectional study focusing on the impact of age and frailty
por: Ambrož, Martina, et al.
Publicado: (2020)

Empagliflozin increases kidney weight due to increased cell size in the proximal tubule S3 segment and the collecting duct
por: Sinha, Frederick, et al.
Publicado: (2023)

Construct and concurrent validity of a patient-reported adverse drug event questionnaire: a cross-sectional study
por: de Vries, Sieta T, et al.
Publicado: (2014)

Empagliflozin and kidney outcomes in Asian patients with type 2 diabetes and established cardiovascular disease: Results from the EMPA‐REG OUTCOME(®) trial
por: Kadowaki, Takashi, et al.
Publicado: (2019)

When drug treatments bias genetic studies: Mediation and interaction
por: Schmidt, Amand F., et al.
Publicado: (2019)

Comparison of Adverse Kidney Outcomes With Empagliflozin and Linagliptin Use in Patients With Type 2 Diabetic Patients in a Real-World Setting
por: Lee, Yueh-Ting, et al.
Publicado: (2021)

Cardiovascular Benefit of Empagliflozin Across the Spectrum of Cardiovascular Risk Factor Control in the EMPA-REG OUTCOME Trial
por: Inzucchi, Silvio E, et al.
Publicado: (2020)

Sex disparities in medication prescribing amongst patients with type 2 diabetes mellitus managed in primary care
por: Ambrož, Martina, et al.
Publicado: (2022)

Relationship between hypoglycaemia, cardiovascular outcomes, and empagliflozin treatment in the EMPA-REG OUTCOME(®) trial
por: Fitchett, David, et al.
Publicado: (2020)

Exposure–Response Analysis of the Sodium–Glucose Cotransporter-2 Inhibitors Dapagliflozin and Empagliflozin on Kidney Hemodynamics in Patients with Type 2 Diabetes
por: van der Hoek, Sjoukje, et al.
Publicado: (2023)

Empagliflozin in Patients with Chronic Kidney Disease
por: Herrington, William G., et al.
Publicado: (2023)

Effect of semaglutide and empagliflozin on cognitive function and hippocampal phosphoproteomic in obese mice
por: Chen, Xiaoyi, et al.
Publicado: (2023)

Cost-effectiveness of empagliflozin for the treatment of heart failure: a systematic review
por: Liu, Jinyu, et al.
Publicado: (2023)

A Review of the Dose Justification of Phase 3 Trials to Regulatory Authorities for Drugs Intended for the Treatment of Type 2 Diabetes in Europe
por: Koomen, Jeroen V., et al.
Publicado: (2021)

Sodium glucose co-transporter 2 inhibition: a new avenue to protect the kidney
por: Heerspink, Hiddo J L
Publicado: (2019)

Effects of sodium–glucose co‐transporter 2 inhibition with empagliflozin on potassium handling in patients with acute heart failure
por: Beusekamp, Joost C., et al.
Publicado: (2021)

Empagliflozin and Cerebrovascular Events in Patients With Type 2 Diabetes Mellitus at High Cardiovascular Risk
por: Zinman, Bernard, et al.
Publicado: (2017)

Using real-world data for supporting regulatory decision making: Comparison of cardiovascular and safety outcomes of an empagliflozin randomized clinical trial versus real-world data
por: Jang, Ha Young, et al.
Publicado: (2022)

Sex Differences in Adverse Drug Reactions of Metformin: A Longitudinal Survey Study
por: de Vries, Sieta T., et al.
Publicado: (2020)

Adverse drug event patterns experienced by patients with diabetes: A diary study in primary care
por: Denig, Petra, et al.
Publicado: (2019)

Progress and opportunities in measuring the burden of Chronic Kidney Disease
por: Vart, Priya, et al.
Publicado: (2022)

Empagliflozin Effectively Attenuates Olanzapine-Induced Body Weight Gain in Female Wistar Rats
por: Ashraf, Ghulam Md, et al.
Publicado: (2021)

Use of a Patient-Friendly Terms List in the Adverse Drug Reaction Report Form: A Database Study
por: de Vries, Sieta T., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_d61eder48pg8fuunvom2h0e913